

peptides were not recognized by said T-cell lines. The sequences of said assayed peptides are as follows: L1-1: GAMDFTTL (SEQ ID NO: 4), L1-2: GDSLFFYL (SEQ ID NO: 5), L1-3: MQVTFIYI (SEQ ID NO: 6), L1-4: VYHIFFQM (SEQ ID NO: 7), L1-5. VHTGFGAM (SEQ ID NO: 8), L1-6: KYPDYIKM (SEQ ID NO: 9), L1-7: VTFIYILV (SEQ ID NO: 10), L1-8: LEDTYRFV (SEQ ID NO: 11), L1-9: GNQLFVTV (SEQ ID NO: 12), L1-10: KKYTFVTV (SEQ ID NO: 13), L1-11: ENDVNYHI (SEQ ID NO: 14), L1-12: AGVDNRECI (SEQ ID NO: 15), L1-13: TVGENVPDDL (SEQ ID NO: 16), L1-14: AQIFNKPYW (SEQ ID NO: 1), L1-15: YKNTNFKEYL (SEQ ID NO: 17)

In the Claims

Replace claims 28 and 31 with the following amended claims re-written in clean form:

- 28. (Amended) A T-cell epitope having an amino acid sequence selected from the group consisting of AQIFNKPYW (SEQ ID NO: 1) and AGVDNRECI (SEQ ID NO: 2).
- 32. (Amended) A T-cell epitope according to claim 29, wherein said variant is structurally homologous to an amino acid sequence selected from the group consisting of AQIFNKPYW (SEQ ID NO: 1) and AGVDNRECI (SEQ ID NO: 2).

REMARKS

The specification has been amended to provide a unique sequence identification number for each nucleotide sequence in the specification. The attached sequence listing has also been inserted into the application. No new matter is introduced by any of these amendments.